Table 2. Examples of completed and active clinical trials using second-generation HIV-1bnAbs for the treatment of HIV-1.

CLINICAL TRIAL IDENTIFIER	BROADLY NEUTRALIZING ANTIBODIES	ENVELOPE BINDING SITE
COMPLETED
NCT02960581	PGT121	V3 glycan
NCT03205917	PGDM1400 PGT121 VRC07-523LS	V1/V2 loop V3 glycan CD4bs
NCT02018510	3BNC117	CD4bs
NCT02446847	3BNC117	CD4bs
NCT02588586	3BNC117	CD4bs
NCT02825797	3BNC117 10-1074	CD4bs V3 glycan supersite
NCT03526848	3BNC117 10-1074	CD4bs V3 glycan supersite
NCT02511990	10-1074	V3 loop
NCT03707977	VRC01LS 10-1074	CD4bs V3 glycan supersite
NCT02664415	VRC01	CD4bs
NCT01950325	VRC01	CD4bs
NCT02840474	VRC01LS VRC07-523LS	CD4bs CD4bs
NCT03254277	3BNC117-LS	CD4bs
NCT04250636	3BNC117-LS 10-1074-LS	CD4bs V3 glycan supersite
NCT03875209	10E8.4	MPER
NCT02579083	VRC01-N	CD4bs
NCT03015181	VRC01-523LS	CD4bs
NCT03837756	3BNC117 10-1074-LS	CD4bs V3 glycan supersite
NCT03041012	3BNC117	CD4bs
ACTIVE
NCT04871113	GSK3810109A	CD4bs
NCT04319367	10-1074-LS	V3 glycan supersite
NCT05300035	10-1074-LS	V3 glycan supersite
NCT03374202	AAV-VRC07	CD4bs
NCT04357821	VRC07-523LS 10-1074	CD4bs V3 glycan supersite
NCT04173819	3BNC117-LS-J 10-1074-LS-J	CD4bs V3 glycan supersite
NCT04983030	PGDM1400 PGT121 VRC07-523LS	V1/V2 loop V3 glycan CD4bs
NCT05281510	VRC07-523LS CAP256V2LS	CD4 V1/V2 loop
NCT05719441	VRC07-523LS PGT121.414.LS	CD4bs V3 glycan